Apellis Pharmaceuticals Inc
The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Apellis Pharmaceuticals Inc in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Apellis Pharmaceuticals Inc.
Recent articles on PMLiVE featuring Apellis Pharmaceuticals Inc
C3G and primary IC-MPGN are estimated to affect 5,000 people in the US
C3G and primary IC-MPGN are estimated to affect 5,000 people in the US and up to 8,000 in Europe
There are currently no treatments that target the underlying cause of C3G or IC-MPGN
The C3 therapy can now be used as a first-line treatment for paroxysmal nocturnal haemoglobinuria
PEGASUS study results show Empaveli is better than Soliris at improving haemoglobin levels
Shares shot up more than 50% in wake of announcement
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology